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Hydrogen peroxide-activatable 
antioxidant prodrug as a targeted 
therapeutic agent for ischemia-
reperfusion injury
Dongwon Lee1,2, Seunggyu Park1, Soochan Bae3, Dahee Jeong1, Minhyung Park1, 
Changsun Kang1, Wooyoung Yoo1, Mohammed A. Samad1,3, Qingen Ke3, Gilson Khang1,2 & 
Peter M. Kang3
Overproduction of hydrogen peroxide (H2O2) causes oxidative stress and is the main culprit in the 
pathogenesis of ischemia/reperfusion (I/R) injury. Suppression of oxidative stress is therefore critical 
in the treatment of I/R injury. Here, we report H2O2-activatable antioxidant prodrug (BRAP) that is 
capable of specifically targeting the site of oxidative stress and exerting anti-inflammatory and anti-
apoptotic activities. BRAP with a self-immolative boronic ester protecting group was designed to 
scavenge H2O2 and release HBA (p-hydroxybenzyl alcohol) with antioxidant and anti-inflammatory 
activities. BRAP exerted potent antioxidant and anti-inflammatory activity in lipopolysaccharide 
(LPS)- and H2O2-stimulated cells by suppressing the generation of ROS and pro-inflammatory 
cytokines. In mouse models of hepatic I/R and cardiac I/R, BRAP exerted potent antioxidant, anti-
inflammatory and anti-apoptotic activities due to the synergistic effects of H2O2-scavenging boronic 
esters and therapeutic HBA. In addition, administration of high doses of BRAP daily for 7 days 
showed no renal or hepatic function abnormalities. Therefore BRAP has tremendous therapeutic 
potential as H2O2-activatable antioxidant prodrug for the treatment of I/R injuries.
Hydrogen peroxide (H2O2) is an essential oxygen metabolite and serves as a messenger in cellular signal 
pathways that are necessary for the growth, development and fitness of living organisms1,2. However, 
H2O2 is one of reactive oxygen species (ROS) and its aberrant accumulation causes oxidative stress and 
inflammation events, which are highly correlated with the onset and development of various pathological 
conditions such as cancer, diabetes, cardiovascular diseases and ischemia-reperfusion (I/R) injury3–5. I/R 
injuries are seen in a variety of clinical conditions such as acute coronary syndrome, hepatic and renal 
ischemic insults, cardiopulmonary bypass surgery and vascular thromboembolic events6–9. Reperfusion 
of blood flow into ischemic tissues induces a large generation of H2O2 which is one of the most common 
ROS and causes oxidative stress and cellular damages, further exacerbating tissue damages10,11. Thus, 
H2O2 is an attractive target of oxidative stress-associated diseases and targeted therapy directed to the 
site of I/R injury, which is characterized by high concentration of H2O2 will offer significant advantages 
over generalized antioxidant therapy.
p-Hydroxybenzyl alcohol (HBA) is one of major active components of Gastrodia elata, which is a 
widely used herbal agent for the treatment of inflammatory diseases and convulsive disorders in oriental 
countries12. HBA exerts antioxidant activities and plays a protective role against oxidative stress-related 
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diseases such as coronary heart diseases and ischemic brain injury13,14. HBA is also a powerful scavenger 
of hydroxyl radical and superoxide due to its phenolic hydroxyl group15,16. Therefore, there has been a 
great interest in the use of HBA as an antioxidant and therapeutic agent17–21. However, HBA is unable to 
scavenge H2O2 and has a short blood circulation time, ~ 30 min of half-life, which would limit its clinical 
applications22.
Medical research has been consistently seeking to develop drugs which have temporal and spatial 
control of therapeutic activities and exhibit desired pharmacological effects23. Prodrugs are a class of 
bioreversible therapeutic molecules that undergo enzymatic or chemical transformation in vivo to gen-
erate the active drug, providing targeted therapeutic activities24,25. In this regard, we developed BRAP as 
a H2O2-activatable antioxidant prodrug of HBA, which can scavenge H2O2 and exert anti-inflammatory 
and anti-apoptotic activities. Herein, we report the potential of BRAP as an I/R targeted therapeutic 
agent using a cell culture model and animal models of I/R injuries.
Results
Synthesis and characterization of BRAP. H2O2-activatable antioxidant prodrug BRAP was synthe-
sized from a simple reaction of (4-(hydroxymethyl)phenyl)boronic acid and 2-(hydroxymethyl)-2-meth-
ylpropane-1,3-diol at room temperature (Fig.  1A). BRAP was obtained as fine white powder and its 
chemical structure was confirmed by NMR (Fig.  1B; Supplementary Fig. S1). Since BRAP containing 
boronic ester was designed to be readily oxidized by H2O2 to generate HBA, boric acid and 2-(hydrox-
ymethyl)-2-methylpropane-1,3-diol, we investigated the sensitivity of BRAP to H2O2 using 1H NMR. 
BRAP was added to D2O containing H2O2 and the changes in the signal were monitored over time. In 
the presence of H2O2, BRAP was oxidized to generate HBA in a H2O2 concentration-dependent manner, 
confirmed by the appearance of new aromatic proton peaks at 6.8 and 7.2 ppm. In the presence of equi-
molar concentration of H2O2 (1 mM), a majority of boronic esters were cleaved within 30 min, with a 
half-life of hydrolysis of ~ 5 min. Nearly all of boronic ester groups were cleaved by 5-fold excess of H2O2 
(5 mM) within 5 min. However, in the absence of H2O2, the boronic ester remained intact even after 3 
days. It was also determined that BRAP undergoes H2O2-triggered hydrolysis with a second-order rate 
constant of 1.67 (Lmol−1 s−1), which is constant with those of substituted phenylboronates26.
It was hypothesized that BRAP could scavenge H2O2 during its H2O2-mediated boronate oxidation. 
We therefore investigated the ability of BRAP to scavenge H2O2 using Amplex Red assay. The addition 
of BRAP resulted in significant reduction in the concentration of H2O2, in a concentration-dependent 
manner (Fig. 2). A majority of H2O2 was scavenged by the same concentration of BRAP within 10 min. In 
contrast, HBA alone (10 μ M) marginally reduced the concentration of H2O2. These observations demon-
strate that BRAP readily reacts with H2O2 to render efficient elimination of H2O2.
Antioxidant and anti-inflammatory activities of BRAP in vitro. We first performed LC-MS/MS 
analysis to confirm if BRAP reacts with H2O2 to generate HBA in cells. Murine macrophage cell line 
RAW264.7 cells were activated with H2O2 for 24 h to induce the further generation of ROS and then cell 
culture medium was replaced with fresh medium. BRAP (1 mM) was added to non-activated or activated 
Figure 1. Generation of H2O2-scavenging antioxidant BRAP. (A) A synthetic route and degradation of 
BRAP as a H2O2-activatable antioxidant prodrug. (B) 1H NMR spectra of BRAP before and after H2O2-
mediated hydrolysis.
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cells and the cell lysates were analyzed with LC-MS/MS. As shown in Supplementary Fig. S2, the gener-
ation of HBA in activated cells was directly confirmed by the appearance of a peak in the LC trace iden-
tical to the standard HBA. However, no peak was observed with non-activated cells, demonstrating the 
BRAP is readily taken up by cells and generates HBA in the presence of intracellular ROS such as H2O2.
Another set of LC-MS/MS experiments was performed to further investigate the H2O2-mediated con-
version of BRAP to HBA in stimulated cells (Fig. 3A). We measured the level of cellular conversion of 
BRAP into HBA in the presence of catalase and uric acid. Catalase and uric acid were used as a scav-
enger of H2O2 and peroxynitrite, respectively27. The addition of catalase (200 μ g) or uric acid (250 μ M) 
attenuated significantly the conversion of BRAP into HBA. Conversion of BRAP into HBA was almost 
completely attenuated in cells in the presence of both catalase and uric acid. However, H2O2-scavenging 
catalase attenuated the cellular conversion of BRAP to HBA to a greater extent than peroxynitrite scav-
enging uric acid, suggesting BRAP preferentially reacts with H2O2 to generate HBA.
We next examined the antioxidant activities of BRAP using RAW264.7 cells. After stimulation by LPS 
(lipopolysaccharide), intracellular ROS production was analyzed by flow cytometry using DCFH-DA 
(dihydrodichlorofluorescein-diacetate) which can be oxidized by the action of various intracellular oxi-
dants such as H2O2, peroxynitrite, and hydroxyl radical to become fluorescent DCF (dihydrodichloroflu-
orescein) (Fig. 3B; Supplementary Fig. S3A)13,28,29. Untreated cells have no significant DCF fluorescence. 
On the other hand, strong DCF fluorescence was observed in the cells treated with exogenous LPS 
because LPS induced the generation of ROS which oxidized DCFH-DA to fluorescent DCF. HBA at 
0.5 mM showed moderate inhibitory effects on ROS generation, as demonstrated in previous studies12,13. 
However, 0.25 mM of BRAP exerted significantly stronger inhibitory effects on the LPS-induced ROS 
generation than 0.5 mM of HBA.
Stimulation with H2O2 for 8 h also induced a large generation of intracellular ROS, evidenced by 
remarkable rightward shift of DCF fluorescence (Fig.  3C; Supplementary Fig. S3B). However, BRAP 
treatment significantly inhibited the cellular generation of ROS in a concentration dependent manner. 
BRAP at 0.5 mM showed more suppressive effects on intracellular ROS generation than 0.5 mM of HBA, 
suggesting the higher antioxidant effects of BRAP than HBA. Stimulation with H2O2 also induced almost 
50% of cell death at 24 h. HBA showed no inhibitory effects on H2O2-mediaed cell death. However, BRAP 
significantly suppressed cell death in H2O2-stimulated cells, in a dose dependent manner (Fig.  3D). 
H2O2-stimulation also enhanced the expression of pro-inflammatory cytokine, TNF-α (tumor necrosis 
factor-alpha). HBA exerted anti-inflammatory activity by suppressing the expression of TNF-α to some 
extent. However, BRAP exerted higher anti-inflammatory activity than HBA (Fig.  3E; Supplementary 
Fig. S4).
Since cardiovascular disease is one of the most common and clinically relevant problems associated 
with oxidative stress injury, we further examined the effect of BRAP on cellular protection from the 
H2O2-induced cell death using adult rat ventricular cardiomyocytes (ARVC) in vitro. We found that H2O2 
(0.25 mM) resulted in approximately 30% cell death. Compared to the vehicle control, HBA showed no 
protective effects, even at 4 mM. However BRAP showed significant protection from H2O2-induced cell 
death in a concentration dependent manner (Fig. 3F).
Nitric oxide is one of major sources of oxidative stress and a well-known pro-inflammatory medi-
ator in the pathogenesis of inflammation14,30. The effects of BRAP on the generation of nitric oxide in 
LPS-treated RAW264.7 cells were studied using a colorimetric assay based on the Griess reaction13,31. 
LPS induced a large amount of nitric oxide production and BRAP exerted the inhibitory effects on nitric 
oxide production in time- and dose-dependent manners (Fig. 3G). HBA alone also inhibited nitric oxide 
production, but only at a concentration higher than 0.5 mM, suggesting superior antioxidant activity of 
BRAP. In order to confirm whether the inhibitory effects of BRAP on nitric oxide generation results 
from the suppression of iNOS (inducible nitric oxide synthases), LPS-stimulated cells were subjected to 
immunoblotting with an antibody of iNOS (Fig. 3H; Supplementary Fig. S5). LPS-induced expression of 
Figure 2. H2O2-scavenging ability of BRAP. H2O2 solution (10 μ M) was mixed with HBA or BRAP for 
10 min and the level of H2O2 was measured by Ample red assay. (n = 4).
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iNOS was significantly suppressed by 0.5 mM of HBA. BRAP also exerted remarkable inhibitory effects 
on iNOS expression. Even 0.25 mM of BRAP almost completely prevented the up-regulation of iNOS and 
displayed more inhibitory effects than 0.5 mM of HBA. The level of nitric oxide is proportional to the 
expression of iNOS. However, we found that BRAP could inhibit the nitric oxide generation only 50%. 
This discrepancy can be explained by the different condition of cell culture. For the detection of nitric 
oxide using Griess reagents, cells were cultured in phenol red-free medium without FBS.
We also investigated the anti-inflammatory effects of BRAP on LPS-stimulated cells by measuring the 
level of inflammatory cytokines such as TNF-α (Fig. 3I). The level of TNF-α was significantly increased 
by the LPS treatment. BRAP significantly suppressed the level of TNF-α . HBA alone also reduced the 
expression of TNF-α , but only at a higher dose than BRAP. These observations from the proof-of concept 
experiments support that rationally designed BRAP is able to scavenge overproduced H2O2 and serves as 
a H2O2-activatable antioxidant. It can be also reasoned that the enhanced antioxidant activity of BRAP 
is contributed to the combined effects of H2O2-scavenging boronic esters and therapeutic HBA released 
after H2O2-mediated boronate oxidation.
Initial cytotoxicity experiments of BRAP demonstrated no significant cytotoxicity at concentrations 
as high as 4 mM after 24 h of incubation in various cell lines and primary culture of ARVC in vitro 
(Supplementary Fig. S6).
Therapeutic efficacy of BRAP in hepatic I/R injury. We investigated whether BRAP could reduce 
ROS generation and inhibit apoptosis in a mouse model of hepatic I/R injury. I/R was induced first by 
1 h of ligation of hepatic artery and portal vein. Then, only hepatic artery was reperfused, which would 
achieve I/R injury to approximately 70% of the liver in the right lower lobe. This method of partial 
ischemia prevents mesenteric venous congestion by allowing portal decompression throughout the right 
Figure 3. Antioxidant and anti-inflammatory effects of BRAP in vitro. (A) Conversion of BRAP into 
HBA in stimulated cells. Values are mean ± s.d. (n = 3). Inhibitory effects of BRAP on the generation 
of intracellular ROS in RAW264.7 cells stimulated by 1 μ g/mL of LPS (B) and 250 μ M of H2O2 (C). The 
generation of ROS was monitored by flow cytometry as an indicator of DCF fluorescence. Fluorescence was 
analyzed in 10,000 cells with excitation at 480 nm and emission at 530 nm. Data are presentative of three 
independent experiments. (D) Effects of BRAP on the viability of RAW264.7 cells activated with H2O2. 
***p < 0.001 vs H2O2. (n = 4). (E) Inhibitory effects of BRAP on the expression of TNF-α in activated 
RAW264.7 cells. Data are presentative of three independent experiments. (F) Protective effects of BRAP 
on H2O2-stimulated adult rat cardiomyocytes. *p < 0.05 vs H2O2. (n = 4). (G) Inhibitory effects of BRAP 
on nitric oxide (NO) generation in LPS-stimulated RAW 264.7 cells. *p < 0.05, **p < 0.01 vs LPS. (n = 4). 
(H) Inhibitory effects of BRAP on the expression of iNOS in LPS-stimulated RAW 264.7 cells. Data are 
presentative of three independent experiments. (I) Inhibitory effects of BRAP on the generation of TNF-α in 
LPS-stimulated RAW 264.7 cells. ***p < 0.001 vs LPS. (n = 4).
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and caudate lobes of the liver and has been widely used in liver I/R model32–34. BRAP (25, 50 or 100 μ g) 
or HBA (50 μ g) was then administrated intraperitoneally (i.p) at the time of reperfusion. I/R induced 
liver damages as evidenced by the increase in alanine transaminase (ALT) in the serum (Fig. 4A). HBA 
at a dose of 50 μ g significantly reduced the ALT activity. BRAP also significantly suppressed the ALT 
activity in a concentration-dependent manner, but showed stronger protective effects than HBA. We 
investigated the inhibitory effects of BRAP on the generation of H2O2 in the liver of mice undergoing 
hepatic I/R injury. As shown in Fig. 4B, the level of H2O2 in the liver was elevated by I/R injury and 50 μ g 
of HBA showed inhibitory effects, but non-significantly. However, the same dose of BRAP significantly 
reduced the level of H2O2, demonstrating the ability of BRAP to scavenge H2O2 in vivo.
Anti-apoptotic activities of BRAP was evaluated by measuring the level of caspase-3, a marker of 
apoptosis. HBA had minimal effects on the cleaved caspase-3. On the other hand, the same dose of BRAP 
significantly inhibited the cleavage of pro-caspase 3. BRAP also remarkably suppressed the expression of 
pro-inflammatory TNF-α (Fig. 4C; Supplementary Fig. S7). These results demonstrate that BRAP exerts 
anti-inflammatory and anti-apoptotic activity during hepatic I/R injury of mice. LC-MS/MS analysis of 
the liver tissues was also performed to further confirm that BRAP could target the site of I/R injury and 
react with H2O2 to generate HBA in liver. As shown in Supplementary Fig. S8, the liver of healthy mice 
treated with BRAP has no HBA peak in the LC trace. However, HBA was detected in the liver of mice 
which was undergoing I/R injury and was also treated with BRAP. No HBA detection was observed in 
lung, heart, kidney and spleen of mice undergoing hepatic I/R injury. These observations demonstrate 
that BRAP targets the hepatic I/R injury and generates HBA from the H2O2-mediated boronate oxidation 
in liver.
Histological analysis demonstrated that severe hepatic damages were induced by I/R, as evidenced 
by disruption of tissue architecture, hepatic necrosis randomly distributed through the parenchyma and 
increased leukocyte infiltration (Fig.  5A). Features of apoptosis were also observed, appearing as cell 
shrinkage, chromatin condensation, dense chromatin fragmentation and formation of apoptotic bod-
ies35,36. HBA showed minimal therapeutic effects on hepatic damages during I/R, but the same dose of 
BRAP resulted in significant attenuation of tissue damages. In order to investigate the effects of BRAP on 
oxidative stress during I/R injury, tissues were stained with dihydroethidium (DHE), which is permeable 
into cells and becomes fluorescent in the presence of oxidants such as superoxide. I/R injury significantly 
increased the oxidative stress, evidenced by the strong purple DHE fluorescence. The level of oxidative 
stress was suppressed by both HBA and BRAP, but BRAP exhibited higher inhibitory effects on ROS 
generation than HBA (Fig. 5B). The addition of selective superoxide scavenger, polyethylene glycolated 
Figure 4. Therapeutic effects of BRAP in hepatic I/R injury. (A) Reduction of the ALT activity by BRAP. 
***p < 0.001 vs Veh, ††p < 0.01 vs HBA. (n = 4). (B) The level of H2O2 in liver tissues determined by Amplex 
Red assay. **p < 0.01 vs Veh, †p < 0.05 vs HBA. ‡p < 0.05 vs sham. (n = 3). (C) Western blot assay of TNF-
α and cleaved caspase-3 in the liver tissues. Actin protein expression was used as an internal control for 
protein loading. Data are representative of three independent experiments. Hepatic I/R injury was induced 
by 1 h ischemia followed by 12 h reperfusion.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:16592 | DOI: 10.1038/srep16592
superoxide dismutase (PEG-SOD) remarkably suppressed the DHE fluorescent signal staining, suggest-
ing that DHE staining is specific for superoxide (Supplementary Fig. S9).
TUNEL (Terminal deoxynucleotidyl transferased UTP nick end labelling) staining was performed to 
investigate the effects of BRAP on apoptotic cell death because it is recently recognized that mediators 
of apoptosis are activated during I/R and post-ischemic cell death is caused by apoptosis37,38. I/R injury 
caused severe hepatic apoptosis, confirmed by the number of strong TUNEL positive cells, which is con-
sistent with other studies reporting that around 15% of apoptotic hepatocytes was measured by TUNEL 
staining after 45 min of ischemia and 24 h of reperfusion32. HBA exhibited modest inhibitory effects on 
hepatic apoptosis, whereas the same dose of BRAP showed significantly greater anti-apoptotic effects 
than HBA (Fig. 5C).
Therapeutic efficacy of BRAP in cardiac I/R injury. The beneficial effects of BRAP were further 
investigated using a mouse model of cardiac I/R injury. After 45 min of ischemia, BRAP (1.5 mg/kg) or 
vehicle was administered i.p. at the time of reperfusion, and then daily (1.5 mg/kg/day) for 2 weeks. For 
cardiac functional analysis, we performed pressure-volume (PV) loop measurement and echocardiogra-
phy at 2 weeks after I/R surgery. PV loop analysis showed a significant reduction of cardiac output (CO), 
stroke work (SW) and ejection fraction (EF) 2 weeks after I/R injury (Fig. 6A; Supplementary Fig. S10A,B). 
Additional cardiac functional analysis using echocardiography also showed significant decrease in frac-
tional shortening (FS) at 2 weeks after I/R surgery (Supplementary Fig. S10C). Administration of BRAP 
significantly attenuated I/R-induced cardiac dysfunction both in PV loop analysis and echocardiography.
We next determined whether the benefits of BRAP after I/R were associated with attenuation of 
oxidative stress, inflammation, and apoptosis. These mechanistic analyses were performed in heart tis-
sues 24 h after cardiac I/R injury. The generation of superoxide was significantly increased after I/R in 
vehicle-treated mice (Fig.  6B,C). BRAP administration significantly decreased DHE staining, demon-
strating the beneficial antioxidant effects of BRAP on I/R. In addition, evaluation of inflammatory 
responses showed that I/R injury significantly increased mRNA levels of TNF-α and monocyte chem-
otactic protein-1 (MCP-1). BRAP administration significantly decreased the expression of TNF-α and 
MCP-1 compared with vehicle-treated mice (Fig.  6D–F). To assess the anti-apoptotic effects of BRAP 
Figure 5. Histological examination of liver tissues of mice undergoing hepatic I/R. (A) Representative 
confocal microscopy images of H&E, DHE and TUNEL staining of liver tissues. (B) Quantification of the 
DHE fluorescent signal in the liver tissues. (C) Quantification of TUNEL positive cells/total cells in the liver 
tissues. ***p < 0.001 vs Veh, ††p < 0.01 vs HBA. (n = 3).
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after I/R, caspase-3 activity assay and TUNEL staining were performed. Caspase-3 activity was sig-
nificantly increased after I/R (Fig.  6G). BRAP effectively inhibited caspase-3 activation. In addition, 
I/R induced the greater extent of cardiomyocyte apoptosis as demonstrated by significant increase in 
TUNEL-positive cardiomyocytes after 24 h of I/R (Fig.  6H,I) which was effectively inhibited by BRAP. 
These results demonstrate that BRAP treatment effectively prevented I/R-induced cardiac damages by 
blocking oxidative stress and inflammation, resulting in inhibition of apoptosis.
Toxicity studies. To determine the potential cumulative toxic effects of BRAP, we administered BRAP 
(1.5 mg/kg/day) daily for 7 days in mice. Serum tests for renal and hepatic functions showed no signifi-
cant abnormalities after 7 days (Fig. 7A,B). In addition, there was no significant histological evidence of 
accumulated toxicity in the different organs after receiving BRAP for 7 days (Fig. 7C). The results of this 
initial toxicity study reveal that BRAP has excellent safety profiles even at the therapeutic dose in vivo.
Discussion
The strategy employed for the development of H2O2-activatable antioxidant prodrug uses phenylbo-
ronic ester groups that can be readily cleaved by H2O2 to generate phenol groups. Boronic ester has 
been widely used as a self-immolative protecting group in the development of molecular sensors, drugs 
and drug delivery systems due to its excellent specific reactivity to H2O2 and nontoxicity3,4,23,39–41. As 
shown in Fig.  1A, we synthesized H2O2-activatable BRAP, (4-(5-(hydroxymethyl)-5-methyl-1,3,2-diox-
aborinan-2-yl)phenyl) methanol. This strategy would allow BRAP to exert a dual mode of therapeutic 
Figure 6. Therapeutic effects of BRAP on cardiac function after I/R. (A) Cardiac Output (CO) after 
BRAP administration for 2 weeks after I/R injury. *p < 0.05 vs sham of each group, †p < 0.05 vs Veh I/R. 
(n = 4). (B) Representative confocal microscopy images of DHE stained cardiomyocytes. (C) Quantification 
of DHE fluorescent signal in the tissue. *p < 0.05 vs sham of each group, †p < 0.05 vs Veh I/R. (n = 3).  
(D) Representative images of mRNA expression of inflammatory markers (TNF-α and MCP-1). 18S 
mRNA expression was used as an internal control. Data are presentative of three independent experiments. 
Quantification of the mRNA expression of caspase-3 activity (E) and MCP-1 (F). *p < 0.05 vs sham of each 
group, †p < 0.05 vs Veh I/R. (n = 3). (G) Quantification of caspase-3 activity after BRAP administration. 
*p < 0.05 vs sham of each group, †p < 0.05 vs Veh I/R (n = 4). (H) Representative confocal microscopy 
images of TUNEL staining of cardiomyocytes. (I) Quantification of TUNEL positive cardiomyocytes/
total cells. *p < 0.05 vs sham of each group, †p < 0.05 vs Veh I/R (n = 3). DHE staining, mRNA expression 
measurement, caspase activity assay and TUNEL analysis were done in heart tissue 24 h after cardiac I/R 
injury.
www.nature.com/scientificreports/
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actions. First, BRAP is specifically oxidized by high level of H2O2, subsequently limiting H2O2-mediated 
oxidative stress and injuries. Second, H2O2-mediated boronate oxidation results in the generation of free 
HBA, which exerts its intrinsic antioxidant and anti-inflammatory activities in the tissues undergoing 
oxidative stress.
Peroxynitrite is a strong biological oxidant with an extremely short half-life of < 10 ms and could have 
deleterious effects on a wide variety of biomolecules such as nucleic acids, proteins and lipids, leading to 
cell apoptosis or necrosis42. Several studies have reported that peroxynitrite stoichiometrically reacts with 
aromatic boronates a million times faster than H2O2 26. However, it has been recently reported that perox-
ynitrite reacts predominantly with carbon dioxide in cells to produce highly strong and short-lived rad-
icals, carbonate radical and nitrogen peroxide that have significantly different chemistries43. Ferrer-Sueta 
et al. reported that carbon dioxide at a physiological concentration (≥ 1.3 mM) is twice as effective as 
20 μ M of boronate at trapping peroxynitrite and a majority of biological reaction of oxidant sensitive 
probes for peroxynitrite are mediated by carbonate radicals and nitrogen peroxide44. Moreover, peroxide 
and peroxynitrite could not be easily distinguished. In this regard, we studied mainly the reactivity of 
BRAP to H2O2 which is highly stable and one of the most abundant ROS in I/R injury.
H2O2 produced during I/R plays an important role by releasing pro-inflammatory cytokines and 
inducing apoptosis, which further exacerbates tissue damages45. Thus, minimizing tissue damages is 
the most important aspect of preserving organ functions and decreasing morbidity and mortality9,46. 
However, the beneficial effects of general antioxidant therapy in human clinical studies have been dis-
appointing47,48. There could be a number of explanations for this finding, such as lack of complete ROS 
inhibition, non-specific suppression of ROS or poor trial design. Although overproduction of H2O2 (in 
μ M) during I/R injury is deleterious, H2O2 at very low levels (in nM) has been shown to be essential for 
cellular signaling for normal physiological cellular functions49. Our approach based on H2O2-activatable 
BRAP will allow effective lowering of H2O2 level only when there is overproduction of H2O2 and spare 
general H2O2 suppression in a normal physiological setting. Thus, our targeted strategy will not only be 
more effective but will also limit undesirable potential side effects.
An ideal targeted drug will exhibit desired pharmacological effects with temporal and spatial con-
trol of therapeutic activities. The goals of the targeted therapy are to have target area specificity and 
Figure 7. Safety profile of BRAP (1.5 mg/kg/day) after daily intraperitoneal administration for 7 
days. (A) The level of creatinine. BRAP has a too low statistical error bar to see. (B) The level of ALT. (C) 
Representative H/E stained tissue sections of different organs. Organs were collected 7 days after daily BRAP 
administration. (n = 4).
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stimulus-sensitivity, which will enhance the effectiveness of the drug as well as simultaneously decrease 
the undesirable side effects50. Although most ROS are extremely short lived, H2O2 is highly stable. 
Consequently, the concentration of H2O2 tends to accumulate in high level during oxidative stress result-
ing in cellular damages. For these reasons, H2O2 is an attractive target for the targeted drug therapy for 
oxidative stress. The ability of BRAP to react with H2O2 will allow it to be activated specifically by a 
pathologic overproduction of H2O2, as seen during I/R injury.
Empirical use of natural products and synthesis of their derivatives have been used for the devel-
opment of new therapeutic drugs51. HBA, one of major active components of Gastrodia elata, plays 
protective roles against brain ischemic injury and coronary artery diseases52. We developed BRAP as a 
H2O2-activatable prodrug of HBA by exploiting H2O2-mediated boronate oxidation as a chemoselective 
approach to react with and scavenge H2O2 in complex biological systems. BRAP with a self-immolative 
boronic ester protecting group is able to scavenge H2O2 and release therapeutic HBA. This property 
allows BRAP to exert highly potent therapeutic effects in tissues that are undergoing oxidative stress in 
a targeted manner. In this study, BRAP displayed remarkable protective actions on hepatic and cardiac 
I/R injury at a dose of less than 5 mg/kg. However, the same dose of HBA showed marginal therapeu-
tic actions. In previous studies using mouse models of ischemic brain injury, HBA exerted sufficient 
therapeutic effects at doses of more than 25 mg/kg17,19,21. Given its lower effective dose and superior 
therapeutic activity of BRAP, BRAP holds great potential as a therapeutic agent for the treatment of 
H2O2-associated diseases.
In addition, masking of HBA by a boronic ester bond also makes it biocompatible and water soluble, 
which provides great benefits in pharmaceutical applications. However, further optimization, including 
administration routes, doses, pharmacokinetics and long-term toxicity are necessary to maximize the full 
potential of BRAP for clinical settings.
To conclude, we have developed H2O2-activatable antioxidant BRAP as an I/R targeted therapeu-
tic agent. BRAP with a self-immolative boronic ester protecting group exerted highly potent antioxi-
dant, anti-inflammatory and anti-apoptotic activities in the site of I/R injuries due to the synergistic 
effects of H2O2-scavenging boronic esters and therapeutic HBA. These findings, we believe, will provide 
foundation for developing a potential drug therapy that will minimize side effects while being able to 
preferentially target the area that is affected during I/R. We anticipate that BRAP could be a novel and 
effective therapeutic option in various oxidative stress-associated conditions, and will have great potential 
in pharmaceutical applications.
Methods
Synthesis of BRAP. (4-(Hydroxymethyl)phenyl)boronic acid (1.50 g) and 2-(hydroxymethyl)-2-meth-
ylpropane-1,3-diol (1.18 g) were added into 20 mL of dry tetrahydrofuran under nitrogen and the mix-
ture was allowed for at room temperature with mechanical stirring. When the reaction mixture became 
clear after 24 h of reaction, 0.2 g of Na2SO4 was added. The reaction was allowed for at room temper-
ature overnight and the solvent was evaporated using a rotary evaporator. BRAP was obtained using 
silica gel chromatography (hexane/ethyl acetate = 70/30). BRAP was characterized using NMR (JNM-
ECA600 JEOL, Peabody, MA) and GC-MS (HP6890 Series GC System, Agilent, Agilent Technologies, 
Willington). 1H NMR (400 MHz, CDCl3): δ 7.7(m, 2 H), 7.3(m, 2 H), 4.6 (m, 2 H, Ar-CH2OH), 3,4 (m, 
2 H, CCH2OH), 0.8(m, 3 H, CCH3); 13C NMR (400 MHz, CDCl3): δ 144.5, 144.0, 127.5, 67.0, 64.5, 63.5, 
42.0, 16.3; GC-MS (m/z):[M+] calc. for C12O4H17B, 236.066; found 235.141. Elemental Analysis (calc, 
found for C12O4H17B): C (61.08, 60.60), H (7.25, 7.29).
Cell culture. RAW 264.7 cells and mouse hepatocytes were obtained from Korean Cell Line Bank 
(Seoul, Korea) and cultured in DMEM containing 10% FBS (fetal bovine serum) with 1% penicillin/
streptomycin. Cells with passage numbers less than 20 were used. All cells were cultured in an incubator 
with 5% of CO2 at 37 °C.
Cytotoxicity and H2O2 scavenging of BRAP. 3-(4,5-Dimethylthiazil-2yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed to evaluate the cytotoxicity of BRAP. Cells were cultured in a 24 
well plate (Nunc™ Cell Culture plate) for 24 h to reach ~80% confluency. Cells were treated with various 
amount of BRAP and incubated for 24 h. Each well was given 100 μ L of MTT solution and was incubated 
for 4 h. Two hundred microlitters of dimethyl sulfoxide (DMSO) was added to each well to dissolve 
the resulting formazan crystals. After 10 min incubation, the absorbance 570 nm was measured using a 
microplate reader (Biotek Instruments, Winooski, VT). The cell viability was determined by comparing 
the absorbance of BRAP treated cells that of control cells.
The ability of BRAP to scavenge H2O2 was evaluated be measuring the concentration of H2O2 after 
incubation with BRAP. After the addition of BRAP (1, 5 or 10 μ M) or HBA (10 μ M) to 1 mL of H2O2 
solution (10 μ M) for 10 min, the concentration of H2O2 was determined using the Amplex Red assay 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
LC-MS/MS analysis of cell lysates. RAW264.7 cells were seeded in a T-75 flask containing 10 mL of 
medium and allowed to attach for 24 h. Cells were stimulated with 250 μ M of H2O2 for 12 h. Then, cells 
were washed with new culture medium and treated with 1 mM of BRAP for 12 h. Cells were washed with 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:16592 | DOI: 10.1038/srep16592
new culture medium and cell pellets were added with 100 μ L of methanol. The mixture was vortexed 
and then additional 900 μ L of methanol was added. The contents were thoroughly mixed by vortexing 
and high molecular materials were removed by sequential centrifugation (10,000 × g) for 10 min. The 
supernatant was immediately stored at − 80 °C until analysis. Upon analysis, 5 μ L was injected and the 
peak for HBA was analyzed using a LC-MS/MS spectrometer (6410 Triple Quad LC /MS/MS, Agilent 
Technologies, Willington) equipped with a column (Synergi 4 μ Hydro RP 80A, 150 × 2.00 mm). The 
mobile phase components were: A = water, 0.1% formic acid; B = acetonitrile, 0.1% formic acid. HBA 
was eluted according to the linear gradient from 5% B buffer to 100% at a flow rate of 0.25 mL/min. 
Multiple reaction monitoring (MRM) was conducted by m/z 124→ 105 for HBA. Ions were generated 
in negative ionization mode using electrospray ionization interface. The fragmenter potential was set to 
50 V and the collision energy was set to 10.
Flow cytometry. RAW 264.7 cells (4 × 105) were cultured in a 24 well culture plate for 24 h and 
treated with LPS (1 μ g/mL) or H2O2 (250 μ M). Cells were treated with HBA or BRAP for 1 h and then 
stimulated with LPS for 1 h or H2O2 for 8 h. For the detection of ROS, DCFH-DA (Sigma-Aldrich, St. 
Louis, MO) was used as ROS probe. The cell suspensions (1 mL) were transferred to a 5 mL culture tube 
containing PBS and added with 5 μ M of DCFH-DA dissolved in DMSO, followed by gentle mixing. The 
cells were incubated for 15 min at 37 °C in the dark and added with 400 μ L of 1× binding buffer. The 
stained cells were analyzed by flow cytometry (FACS Caliber, Becton Dickinson, San Jose, CA). A total 
of 1.0 × 104 events were counted for each sample.
Detection of nitric oxide. RAW 264.7 cells (4 × 105 cells/well in a 24 well plate) were cultured in 
phenol red-free medium without FBS and pretreated with 3 μ L of LPS (1 mg/mL) in the presence of 
various amounts of BRAP for 4 h. Cell culture medium was replaced with fresh medium and cells were 
incubated for 8 h. The concentration of nitric oxide was determined using a colorimetric assay based on 
the Griess reaction. Fifty microlitters of cell culture medium was collected and given 100 μ L of Griess rea-
gent (6 mg/mL) at room temperature for 10 min, and then the nitric oxide concentration was determined 
by measuring the absorbance at 570 nm using a microplate reader (Synergy MX, BioTek Instruments, 
Inc, Winooski, VT). The standard curve of nitric oxide was constructed using known concentrations of 
sodium nitrite. Untreated cells were used as negative control.
Immunoblot analysis. Cells (2 × 106/well) cells were treated with various concentrations of BRAP 
24 h in the presence of LPS (1 μ g/mL) or H2O2 (250 μ M) and then washed with fresh PBS twice. Proteins 
were extracted from the cells using a RIPA buffer (Thermo Scientific, Rockford, IL) on ice and the protein 
content was measured using BCA assay. Electrophoresis was performed using 20 μ g of cell lysate on a 
10% polyacrylamide gel under the same conditions and proteins were transferred to PVDF membranes 
(Millipore, Billerica, MA). The blot was incubated with iNOS monoclonal antibody or TNF-α mono-
clonal antibody (Santa Cruz Biotechnology, Dallas, TX) at a 1:1000 dilution ratio and HRP-conjugated 
anti-goat (Millipore, Billerica, MA) which is used as a secondary antibody. Actin protein expression was 
used as an internal control for protein loading. Immunoblot signals were developed using SuperSignal 
Ultra chemiluminescent reagent (Pierce, Rockford, IL). Images have been cropped for presentation. 
Full-length images of blots are presented in Supplementary Information.
Animal surgeries. Hepatic I/R surgery was performed in 12 week-old male mice as described pre-
viously10. Briefly, mice (8 weeks old and 20 g, Balb/c, Orient Bio, Korea) were anaesthetized with intra-
peritoneal injection of mixed solution of ketamine and Xylazine (8:1 ratio), and midline incision was 
performed for laparotomy. After identifying the portal triad and biliary tree, the main trunk of hepatic 
artery and portal vein were clamped with vascular clip except for the vasculatures to the right lower 
lobe to achieve ischemic injury to approximately 70% of the liver. After 1 h of ischemia, reperfusion was 
achieved by releasing the vascular clip. No vascular clamp was done for the sham group of mice. After 
1 h, reperfusion was achieved by releasing the vascular clip. Immediately, BRAP (25, 50 or 100 μ g) or 
HBA (50 μ g) was intraperitoneally given to mice. The same amount of saline was given to sham groups. 
Then, the incision was closed with 5–0 black silk suture. For LC-MS/MS analysis, 4 h after reperfusion, 
liver, lung, heart, kidney and spleen were removed and homogenized on ice. The tissue lysates were 
analyzed for detection of HBA using a LC-MS/MS spectrometer (6410 Triple Quad LC /MS/MS, Agilent 
Technologies, Willington) equipped with a column (Synergi 4 μ Hydro RP 80A, 150 × 2.00 mm). All the 
animal experiments were carried out according to the guidelines of the institution animal ethical com-
mittee of Chonbuk National University, Korea.
Cardiac I/R surgery was performed in 12 week-old male mice as described previously53. Briefly, mice 
were anaesthetized with intraperitoneal injection of mixed solution of ketamine and Xylazine (8:1 ratio), 
and placed on a rodent ventilator (model 687, Harvard Respirator). After thoracotomy, the left anterior 
descending artery (LAD) artery was identified and ligated with a 7–0 silk suture tied around a spe-
cialized 30G-catheter. The animal remained under anesthesia and ventilation for 45 min of ischemia, 
after which reperfusion was achieved by cutting the suture and re-establishing arterial perfusion. Sham 
operated mice underwent the same procedure without LAD occlusion. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.
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Amplex red assay of liver tissue. Liver tissues were randomly collected in PBS with the same weight/
volume ration and homogenized using a homogenizer (PRO Scientific, PRO 200). Tissue homogenates 
were centrifuged at 1,000 × g at 4 °C for 10 min and the supernatants were collected. The supernatant 
was treated with Amplex Red assay reagents (Invitrogen, Carlsbad, CA) and incubated at room tem-
perature for 30 min. The concentration of H2O2 in the supernatant was determined using a microplate 
reader (Synergy MX, BioTek Instruments, Inc, Winooski, VT) with excitation at 530 nm and emission 
at 590 nm.
Cardiac functional analysis. Cardiac function was evaluated using the pressure-volume loop meas-
urement and echocardiography 2 weeks after I/R as described previously54. Pressure-volume parameters 
were measured after isoflurane (2%) inhalant anesthesia using a 1.4 Fr. micro-tip pressure-volume cath-
eter (ScisenseInc, Ontario, Canada) inserted into the right common carotid artery. The catheter was 
gently advanced into the left ventricle to obtain LV hemodynamic parameters. Data was recorded using 
a Powerlab system (ADInstruments, Colorado Springs, CO). Beat by beat pressure-volume parameters 
including heart rate (HR), stroke volume (SV), stroke work (SW) and cardiac output (CO) were meas-
ured and analyzed using CardioSoft Pro software (CardioSoft, Houston, TX). Transthoracic echocardiog-
raphy was performed using a Vevo2100 ultra-high frequency small animal imaging system with MS400 
transducer (18–38 MHz) (Visualsonics, Tronto, Canada).
ALT activity assay. Livers were removed from the mice and homogenized in PBS. Total serum pro-
teins were extracted from the tissue homogenate according to the manufacturer’s suggested protocol. The 
activity of serum ALT was determined with an ALT enzymatic assay kit (Asan Pharma, Seoul, Korea) 
using a microplate reader (Synergy MX, BioTek Instruments, Inc, Winooski, VT).
Apoptosis assays. For liver apoptosis assay, terminal deoxynucleotidyl transferased UTP nick end 
labeling (TUNEL) staining was performed using a DeadEndTM Fluorometric TUNEL kit (Promega, 
Madsion, WI). Tissue sections were stained for nuclei (4′ ,6-diamidino-2-phenylindole (DAPI) staining) 
and apoptotic nuclei (TUNEL staining) and analyzed using a confocal laser scanning microscope. For 
heart tissues, TUNEL staining was performed using in situ cell death detection Kit (Roche Applied Science, 
Indianapolis, IN) as described previously. To distinguish cardiomyocyte from non-cardiomyocyte nuclei, 
we used triple stain for nuclei (DAPI staining), apoptotic nuclei (TUNEL staining), and cardiomyocytes 
(α -Actinin staining), and analyzed the stained sections using confocal microscopy. A minimum of ~10 
high power fields with ~2000 nuclei/field were counted for each sample.
RNA isolation and reverse transcription -polymerase chain reaction (RT-PCR). The tissue 
samples were homogenized in TRIzol reagent (Life Technologies, Gaithersburg, MD) and total RNA 
was extracted from the tissue according to the manufacturer’s suggested protocol. Each sample was 
treated with DNase I (Gibco BRL, Rockville, MD) to eliminate any possible DNA contamination. Total 
RNA concentration was determined from spectrophotometric optical density measurement (260 and 
280 nm). Reverse transcriptase reactions were then carried out using the RNA PCR Core Kit (PE Applied 
Biosystems, Foster City, CA). Each reaction tube contained 10 μ g of total RNA in a volume of 150 μ l 
containing 5 mmol/L MgCl2, 1 × PCR Buffer II, 500 μ mol/L of each dNTP, 0.6 U/μ l of RNase inhibitor, 
2.5 U/μ l of MuLV Reverse Transcriptase, 2.5 μ mol/L of random hexamers and DEPC-treated water to 
volume. Reverse transcriptase reactions were carried out in a DNA Thermal Cycler 480 (Perkin Elmer, 
Branchburg, NJ) at 42 °C for 20 min and 99 °C for 5 min. The cDNA was then stored at − 20 °C. mRNA 
expression levels were analyzed by RT-PCR with following specific primers: for pro-inflammatory factors, 
tumor necrosis factor-α (TNF-α ) sense, 5′ -CCT CAG CCT CTT CTC CTT CCT-3′ , TNF-α antisense, 
5′ -GGT GTG GGT GAG GAG CA-3′ , monocyte chemotactic protein-1 (MCP-1) sense, 5′ -ACC TGC 
TGC TAC TCA TTC AC-3′ , MCP-1 antisense, 5′ -TTG AGG TGG TTG TGG AAA AG-3′ , 18S sense, 
5-GTT ATG GTT CCT TTG TCG CTC GCT C-3, 18S anti-sense, 5-TCG GCC CGA GGT TAT CTA 
GAG TCA C-3. PCR was performed using the Universal PCR Master Mix, 100 nmol/L of primers and 
various concentrations of RT product. Amplification conditions included 2 min at 50 °C and 10 min at 
95 °C, and then run for 40 cycles at 95 °C for 15 sec and 60 °C for 1 min on the ABI PRISM 7700 sequence 
detection system (PE Applied Biosystems). Standard curves were constructed on a 1:2 serial dilution of 
DNA Template Reagent (PE Applied Biosystems). The threshold cycle, which represents the PCR cycle 
at which an increase in reporter fluorescence above background is first detected, was determined by the 
software, based on the generated standard curves. For RT-PCR ribosomal 18S primers acted as internal 
controls and all RT-PCR signals were normalized to the 18S signal of the corresponding RT products.
Caspase-3 activity assay. The hearts were frozen in liquid nitrogen and homogenized in caspase 
lysis buffer (20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 
0.1 mM PMSF, 10 μ g/ml leupeptin, 2 μ g/ml aprotinin) for 15 min. on ice. They were then mechanically 
disrupted and centrifuged at 15,000 × g for 20 min to obtain cell lysates. Equal amounts of proteins were 
incubated with 50 μ M of caspase substrate in caspase reaction buffer mM 50 HEPES (pH 7.4), 75 mM 
NaCl, 0.1% CHAPS, 2 mM DTT in a 96-well microplate at 37 °C for 1 h. The activity of caspase-3 was 
determined with colorimetric assay kit (R&D Systems, Minneapolis, MN) as described previously53,55. 
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Briefly, protein samples were added to substrates of Acetyl-Asp-Glu-Val-Asp-p-nitroanilide. The 
enzyme-catalyzed release of p-nitroanilide was measured using a spectrometer at 405 nm.
Reactive oxygen species (ROS) staining. The optimal cutting temperature (OCT)-embedded tis-
sues were fixed in 4% paraformaldehyde. Tissue sections were incubated with 5 μ M dihydroethidium at 
37 °C for 30 min in a humidified chamber protected from light. Then, 4′ ,6-diamidino-2-phenylindole was 
applied. Images were acquired by confocal fluorescence microscope.
Statistical analyses. Values were expressed as mean ± s.d. Comparisons between and within groups 
were conducted with unpaired Student t-tests and repeated-measures ANOVA using GraphPad Prism 5.0 
(San Diego, CA), respectively. Probability (p) values of < 0.05 were considered significant.
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